Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push

Danish drugmaker Novo Nordisk has secured exclusive global rights to Omeros' experimental drug zaltenibart, designed for rare blood and kidney disorders like paroxysmal nocturnal hemoglobinuria (PNH), through a licensing deal valued at up to $2.1 billion. The agreement includes $340 million in upfront and near-term milestone payments, significantly bolstering Novo Nordisk's pipeline in rare diseases. Following the announcement, Omeros's shares surged threefold in premarket trading, reflecting strong investor confidence in the drug's potential and the substantial financial terms of the partnership.

Analysis

Danish drugmaker Novo Nordisk has secured exclusive global rights to Omeros' experimental drug zaltenibart through a licensing deal valued at up to $2.1 billion, including $340 million in upfront and near-term milestone payments. This significant transaction, categorized under M&A & Restructuring and Healthcare & Biotech themes, immediately propelled Omeros' shares to jump threefold to $12.32 in premarket trading, reflecting a strongly positive market sentiment.

Zaltenibart, designed to inhibit MASP-3, targets rare blood and kidney disorders, notably paroxysmal nocturnal hemoglobinuria (PNH), for which late-stage trials began in March. The drug has demonstrated potential advantages over existing or developing alternative pathway inhibitors, showing safety and tolerability in trials, which aligns with Novo Nordisk's strategic expansion into rare disease treatments.

For Novo Nordisk, this deal strengthens its pipeline, with plans to initiate a global program for zaltenibart in PNH and explore other indications post-deal closing in Q4 2025. Omeros benefits from substantial non-dilutive capital, while retaining focus on securing approval for its other experimental drug, narsoplimab, this quarter, and holding certain rights to preclinical MASP-3 programs.

This agreement provides Omeros with significant financial backing and validation for its pipeline, while offering Novo Nordisk a promising late-stage asset in a specialized therapeutic area. The deal underscores the strategic value of innovative rare disease therapies in the biopharmaceutical sector.

Key Decisions for Investors

• Investors in Omeros (OMER) should recognize the immediate financial uplift and pipeline validation, while closely monitoring the deal's Q4 2025 closing and narsoplimab's regulatory progress.
• Novo Nordisk (NVO) investors should view this as a strategic expansion into rare disease therapeutics, potentially enhancing long-term growth prospects through a promising late-stage asset.
• Both sets of investors should track zaltenibart's clinical development and regulatory milestones, alongside Omeros's independent pipeline advancements, for future valuation adjustments.